INT184815

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.83
Pain Relevance 0.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (ETF1) RNA binding (ETF1) translation (ETF1)
cytoplasm (ETF1)
Anatomy Link Frequency
Impression 1
ETF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
methadone 1 96.96 Very High Very High Very High
cocaine 5 95.56 Very High Very High Very High
addiction 3 95.24 Very High Very High Very High
drug abuse 6 85.72 High High
depression 4 84.96 Quite High
alcohol 3 74.20 Quite High
Clonidine 8 72.96 Quite High
headache 2 13.12 Low Low
Biofeedback 46 5.00 Very Low Very Low Very Low
Dopamine 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Stress 6 99.20 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 147 97.64 Very High Very High Very High
Cocaine Dependence 2 95.56 Very High Very High Very High
Substance Abuse 17 85.72 High High
Depression 4 84.96 Quite High
Anxiety Disorder 5 77.04 Quite High
Manic Depressive Disorder 1 76.16 Quite High
Psychosis 4 75.44 Quite High
Coronary Artery Disease 6 74.08 Quite High
Aggression 3 64.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This property is used to control the resistive forces of the ERF FP actuator.
Regulation (control) of ERF FP actuator
1) Confidence 0.40 Published 2005 Journal J Neuroengineering Rehabil Section Body Doc Link PMC1180467 Disease Relevance 0.24 Pain Relevance 0
These chains alter the ERF's viscosity, yield stress, and other properties, allowing the ERF to change consistency from that of a liquid to something that is viscoelastic, such as a gel.
Regulation (alter) of ERF associated with stress
2) Confidence 0.35 Published 2005 Journal J Neuroengineering Rehabil Section Body Doc Link PMC1180467 Disease Relevance 0.10 Pain Relevance 0
In a 7-week randomized controlled trial, adult ADHD symptom reduction as measured by the Clinical Global Impression scale was 50% for methylphenidate, 64% for sustained-release bupropion and 27% for placebo.67 A 12-week trial comparing the efficacy of sustained-release MPH or sustained-release bupropion to placebo in treating ADHD symptoms in methadone-maintained subjects with cocaine dependence or abuse did not show any significant difference between treatments because of a high placebo response.
Regulation (efficacy) of sustained-release in Impression associated with addiction, methadone, attention deficit hyperactivity disorder and cocaine
3) Confidence 0.00 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 1.49 Pain Relevance 0.54

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox